Houston founder on shaping the future of medicine through biotechnology and resilience

Guest Column

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

Living with chronic disease has shaped my life in profound ways. My journey began in 5th grade when I was diagnosed with Scheuermann’s disease, a degenerative disc condition that kept me sidelined for an entire year. Later, I was diagnosed with hereditary neuropathy with liability to pressure palsies (HNPP), a condition that significantly impacts nerve recovery. These experiences didn’t just challenge me physically, they reshaped my perspective on healthcare — and ultimately set me on my path to entrepreneurship. What started as personal health struggles evolved into a mission to transform patient care through innovative biotechnology.

A defining part of living with these conditions was the diagnostic process. I underwent nerve tests that involved electrical shocks to my hands and arms — without anesthesia — to measure nerve activity. The pain was intense, and each test left me thinking: There has to be a better way. Even in those difficult moments, I found myself thinking about how to improve the tools and processes used in healthcare.

HNPP, in particular, has been a frustrating condition. For most people, sleeping on an arm might cause temporary numbness that disappears in an hour. For me, that same numbness can last six months. Even more debilitating is the loss of strength and fine motor skills. Living with this reality forced me to take an active role in understanding my health and seeking solutions, a mindset that would later shape my approach to leadership.

Growing up in Houston, I was surrounded by innovation. My grandfather, a pioneering urologist, was among the first to introduce kidney dialysis in the city in the 1950s. His dedication to advancing patient care initially inspired me to pursue medicine. Though my path eventually led me to healthcare administration and eventually biotech, his influence instilled in me a lifelong commitment to medicine and making a difference.

Houston’s thriving medical and entrepreneurial ecosystems played a critical role in my journey. The city’s culture of innovation and collaboration provided opportunities to explore solutions to unmet medical needs. When I transitioned from healthcare administration to founding biotech companies, I drew on the same resilience I had developed while managing my own health challenges.

My experience with chronic disease also shaped my leadership philosophy. Rather than accepting diagnoses passively, I took a proactive approach questioning assumptions, collaborating with experts, and seeking new solutions. These same principles now guide decision-making at FibroBiologics, where we are committed to developing groundbreaking therapies that go beyond symptom management to address the root causes of disease.

The resilience I built through my health struggles has been invaluable in navigating business challenges. While my early career in healthcare administration provided industry insights, launching and leading companies required the same determination I had relied on in my personal health journey.

I believe the future of healthcare lies in curative treatments, not just symptom management. Fibroblast cells hold the promise of engaging the body’s own healing processes — the most powerful cure for chronic diseases. Cell therapy represents both a scientific breakthrough and a significant business opportunity, one that has the potential to improve patient outcomes while reducing long-term healthcare costs.

Innovation in medicine isn’t just about technology; it’s about reimagining what’s possible. The future of healthcare is being written today. At FibroBiologics, our mission is driven by more than just financial success. We are focused on making a meaningful impact on patients’ lives, and this purpose-driven approach helps attract talent, engage stakeholders, and differentiate in the marketplace. Aligning business goals with patient needs isn’t just the right thing to do, it’s a powerful model for sustainable growth and lasting innovation in biotech.

---

Pete O’Heeron is the CEO and founder of FibroBiologics, a Houston-based regenerative medicine company.

From Your Site Articles

FibroBiologics has opened a new 10,000-square-foot Houston lab to scale up research efforts and pave the way for in-house manufacturing. Photo via Fibrobiologics.com

Houston regenerative medicine company expands lab for future trials

new digs

A Houston regenerative medicine company has unveiled new laboratory space with the goal of expanding its pioneering science.

FibroBiologics uses fibroblasts, the body’s most common type of cell, rather than stem cells, to help grow new cells. Fibroblasts are the primary variety of cells that compose connective tissue. FibroBiologics has found in studies that fibroblasts can be even more powerful than stem cells when it comes to both regeneration and immune modulation, meaning they could be a more versatile way forward in those fields.

In 2023, FibroBiologics moved into new lab space in the UH Technology Bridge. Now, with its new space, the publicly traded company, which has more than 240 patents issued or pending, will be even better equipped to power forward with its research.

The new space includes more than 10,000 square feet of space devoted to both labs and offices. The location is large enough to also house manufacturing drug product candidates that will be used in upcoming trials. Additionally, the company reports that it plans to hire additional researchers to help staff the facility.

“This expansion marks a transformative step forward for our company and our mission,” Pete O’Heeron, FibroBiologics founder and CEO, said in a news release. “By significantly increasing the size of our lab, we are creating the space and infrastructure needed to foster greater innovation and accelerate scientific breakthroughs.”

The streamlined, in-house manufacturing process will reduce the company’s reliance on external partners and make the supply chain simpler, O’Heeron added in the release.

Hamid Khoja, the chief scientific officer for FibroBiologics, also chimed in.

“To date, our progress in developing potentially transformative therapeutic candidates for chronic diseases using fibroblasts has been remarkable,” he added in the release. “This new laboratory facility will enable further expansion and acceleration of our research and development efforts. Additionally, the expansive new space will enable us to bring in-house currently outsourced projects, expand our science team and further contribute to the increased efficiency of our R&D efforts.”

This news arrives shortly after a milestone for the company in its research about neurodegenerative disease. Last month, fibroblast treatments in an animal model study demonstrated a notable regeneration of the myelin sheath, the layer that insulates nerves and is worn down by disease.

“Confirming remyelination in a second validated animal model is an important step in our research and development efforts, offering fresh hope for patients with demyelinating diseases, including multiple sclerosis,” O’Heeron added in a separate release. “These findings advance our mission to develop transformative fibroblast-based therapies that address the root causes of chronic disease, not just their symptoms, and reflect our dedication to pushing the frontiers of regenerative medicine."

FibroBiologics will IPO this week. Photo via Getty Images

Houston regenerative medicine company to IPO, move toward more human trials

ready to list

Want a piece of one of Houston’s most promising biotech companies? On January 31, FibroBiologics will begin the trading of its common stock on the Nasdaq stock exchange.

While most labs in the realm of regenerative medicine are focused on stem cells, FibroBiologics has bet on fibroblasts as the secret to treating myriad ailments. Fibroblasts, the most common type of cell in the body, are the primary cells that compose connective tissue.

Interested investors can find a prospectus to peruse before taking the leap. FibroBiologics filed with the U.S. Securities & Exchange Commission (SEC) on November 7, 2023. In September, FibroBiologics CEO Pete O’Heeron told InnovationMap, “I think what we're going to see is that fibroblasts are going to end up winning... They're just a better overall cell than the stem cells.”

O’Heeron was first exposed to the possibilities of fibroblasts as a means of regrowing discs in the spine. Since starting the company in 2008 as SpinalCyte, O’Heeron and FibroBiologics have organically written and filed more than 320 patents. Potential treatments go far beyond spinal surgery to include wound care, cancer, and multiple sclerosis.

According to O’Heeron, the goal in going public is to raise capital for human trials.

“We’ve had really fantastic results with animals and now we’re ready for humans,” he explained in September. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

FibroBiologics is growing with impressive speed. O’Heeron told us that he is hiring as quickly as he is able to find qualified scientists with the expertise to do the one-of-a-kind work required. The company opened a new lab last fall at the UH Technology Bridge, Newlin-Linscomb Lab for Cell Therapies. With its new status as a publicly traded company, FibroBiologics is primed to break even more ground.

FibroBiologics is opening a unique new lab at the University of Houston's Technology Bridge. Photo by Natalie Harms/InnovationMap

Houston regenerative medicine company opens new lab at UH

cell therapy innovation

Pete O’Heeron wants you to know that “Bohemian Rhapsody” was originally released as a B-side. What does this nugget about Queen have to do with regenerative medicine? For O’Heeron and his company, FibroBiologics, it means everything.

That’s because most scientists consider stem cells the A-side when it comes to the race to curing disease. But FibroBiologics has set its sights on fibroblasts. The most common cell in the body, fibroblasts are the main cell type in connective tissue.

“Everyone was betting on stem cells, and we started betting on fibroblasts,” says O’Heeron, who started the company in 2008 as SpinalCyte. “I think what we're going to see is that fibroblasts are going to end up winning, there are more robust, more that are lower cost cell, they have higher therapeutic values, higher immune modulation. They're just a better overall cell than the than the stem cells.”

Since a neurosurgeon and a dermatologist first introduced O’Heeron to the idea of using fibroblasts to regrow discs in the spine, the company has expanded its reach to include promising treatments for multiple sclerosis and cancer and in wound care. Imagine a world where doctors lay fibroblasts directly onto surgical incisions after surgery, cutting the time for healing in half.

FibroBiologics has organically written and filed more than 320 patents.

“It's quite a unique situation. I don’t think that in other areas of science that you have such a wide open area to go out and patent. It's just it was a brand new area nobody had been working on,” O’Heeron explains.

And soon, investors will be able to own a stake in the impressive work being forged in Houston. FibroBiologics, previously FibroGenesis, was formed in order to go public in a direct NASDAQ listing. The goal is to access the capital necessary to go to human trials. Earlier this year, the company also launched a crowdfunding campaign.

“We’ve had really fantastic results with animals and now we’re ready for humans,” says O’Heeron. “We've done small human trials, but we haven't done the large ones that are going to get the commercialization approval from the FDA.”

With that in mind, the company just signed a deal with University of Houston’s Innovation Center. On Thursday, September 7, FibroBiologics will dedicate the Newlin-Linscomb Lab for Cell Therapies in the UH Technology Bridge. The new lab is named for former player and color commentator for the Houston Rockets, Mike Newlin and his wife, Cindy, as well as Pam and Dan Linscomb, a founding partner of Kuhl-Linscomb, one of the largest wealth management companies in Houston.

Other big local names newly attached to the company are astronaut Kate Rubins and Elizabeth Shpall, the director of the cell therapy laboratory at MD Anderson Cancer Center. Both have joined FibroBiologics as members of its scientific advisory board.

To fill the lab, O’Heeron says that he is adding to his team as quickly as he is able. The barrier is the fact that there are few, if any people in the world with the exact qualifications he’s seeking.

“Anytime you're breaking new scientific ground, you can't really just go out and recruit someone with that background because it really doesn't exist,” he says. But he is willing to teach and challenge scientists who are the right fit, and is hoping to expand the team in the new lab.

But like Queen did in 1975, FibroBiologics is pioneering a category of its own. And that’s something worth betting on.

This week's roundup of Houston innovators includes Ben Jawdat of Revterra, Pete O'Heeron of FibroBiologics, and Jay Manouchehri of Fluence Analytics. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to clean energy — recently making headlines in Houston innovation.

Ben Jawdat, CEO and founder of Revterra

Ben Jawdat, CEO and founder of Revterra, joins the Houston Innovators Podcast. Photo via LinkedIn

Ben Jawdat founded Revterra in Houston based on a unique kinetic energy storage technology. The company has created away to better optimize existing grid-based electric vehicle charging ports while still minimizing a carbon footprint. The startup hopes to be a major player within the energy transition.

"We really want to be an enabling technology in the renewable energy transition," Jawdat says. "One part of that is facilitating the development of large-scale, high-power, fast-charging networks. But, beyond that, we see this technology as a potential solution in other areas related to the clean energy transition."

He shares more about what's next for Revterra on the podcast. Read more and listen to the episode.

Pete O'Heeron, CEO and chairman of FibroBiologics

Pete O'Heeron leads FibroBiologics as CEO and chairman. Photo via Fibrobiologics.com

FibroBiologics, which is developing fibroblast cell-based therapeutics for chronic diseases, launched a campaign with equity crowdfunding platform StartEngine. The platform lets anyone — regardless of their net worth or income level — to invest in securities issued by startups.

The funding, according to a press release, will be used to support ongoing operations of Fibrobiologics and advance its clinical programs in multiple sclerosis, degenerative disc disease, wound care, extension of life, and cancer.

"We're excited to partner with StartEngine on this campaign. StartEngine has over 600,000 investors as part of their community and has raised over half a billion dollars for its clients," says FibroBiologics' Founder and CEO Pete O'Heeron, in the release. Read more.

Jay Manouchehri, CEO of Fluence Analytics

Fluence Analytics has exited to a multinational Japanese engineering and software giant. Image via FluenceAnalytics.com

Yokogawa, which has its US operations based in Sugar Land, acquired Fluence Analytics Inc. in a deal announced last week. The terms of the deal were not disclosed and, effective immediately, the company operate as Yokogawa Fluence Analytics. Jay Manouchehri, who joined the company in 2022, will continue to serve as CEO of the entity.

“Combining forces with Yokogawa Electric enables us to capture the full value of our unique data sets, and we can't wait to deliver this added value to our customers," Manouchehri says in a news release. "Together, we will enable autonomous operations and digital transformation in the polymer and biopharma industries."

Founded in 2012 in New Orleans, Fluence Analytics moved to Houston in 2021 following a $7.5 million venture capital raise led by Yokogawa Electric Corp., which has its North American headquarters in Sugar Land. Read more.

You can now hop online and invest in this promising cell therapy startup. Photo via Getty Images

Houston biopharma company launches equity crowdfunding campaign

money moves

A clinical-stage company headquartered in Houston has opened an online funding campaign.

"This is an exciting time at FibroBiologics as we continue progressing our clinical pipeline and developing innovative therapies to treat chronic diseases," he continues. "This new funding will fuel our growth in the lab and bring us one step closer to commercialization."

The campaign, launched this week, already has over 100 investors, at the time of publication, and has raised nearly $2 million, according to the page. The minimum investment is set at around $500, and the company's indicated valuation is $252.57 million.

In 2021, FibroBiologics announced its intention of going public. Last year, O'Heeron told InnovationMap on the Houston Innovators Podcast of the company's growth plans as well as the specifics of the technology.

Only two types of cells — stem cells and fibroblasts — can be used in cell therapy for a regenerative treatment, which is when specialists take healthy cells from a patient and inject them into a part of the body that needs it the most. As O'Heeron explains in the podcast, fibroblasts can do it more effectively and cheaper than stem cells.

"(Fibroblasts) can essentially do everything a stem cell can do, only they can do it better," says O'Heeron. "We've done tests in the lab and we've seen them outperform stem cells by a low of 50 percent to a high of about 220 percent on different disease paths."

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

2 UH projects named finalists for $50M fund to shape future of Gulf Coast

Looking to the Future

Two University of Houston science projects have been selected as finalists for the Gulf Futures Challenge, which will award a total of $50 million to develop ideas that help benefit the Gulf Coast.

Sponsored by the National Academies of Science, Engineering and Medicine’s Gulf Coast Research Program and Lever for Change, the competition is designed to spark innovation around problems in the Gulf Coast, such as rising sea levels, pollution, energy security, and community resiliency. The two UH projects beat out 162 entries from organizations based in Alabama, Florida, Louisiana, Mississippi, and Texas.

“Being named a finalist for this highly competitive grant underscores the University of Houston’s role as a leading research institution committed to addressing the most pressing challenges facing our region,” said Claudia Neuhauser, vice president for research at UH.

“This opportunity affirms the strength of our faculty and researchers and highlights UH’s capacity to deliver innovative solutions that will ensure the long-term stability and resilience of the Gulf Coast.”

One project, spearheaded by the UH Repurposing Offshore Infrastructure for Continued Energy (ROICE) program, is studying ways to use decommissioned oil rig platforms in the Gulf of Mexico as both clean energy hydrogen power generators as well a marine habitats. There are currently thousands of such platforms in the Gulf.

The other project involves the innovative recycling of wind turbines into seawall and coastal habitats. Broken and abandoned wind turbine blades have traditionally been thought to be non-recyclable and end up taking up incredible space in landfills. Headed by a partnership between UH, Tulane University, the University of Texas Health Science Center at Houston, the city of Galveston and other organizations, this initiative could vastly reduce the waste associated with wind farm technology.

wind turbine recycled for Gulf Coast seawall. Wind turbines would be repurposed into seawalls and more. Courtesy rendering

"Coastal communities face escalating threats from climate change — land erosion, structural corrosion, property damage and negative health impacts,” said Gangbing Song, Moores Professor of Mechanical and Aerospace Engineering at UH and the lead investigator for both projects.

“Leveraging the durability and anti-corrosive properties of these of decommissioned wind turbine blades, we will build coastal structures, improve green spaces and advance the resilience and health of Gulf Coast communities through integrated research, education and outreach.”

The two projects have received a development grant of $300,000 as a prize for making it to the finals. When the winner are announced in early 2026, two of the projects will net $20 million each to bring their vision to life, with the rest earning a consolation prize of $875,000, in additional project support.

In the event that UH doesn't grab the grand prize, the school's scientific innovation will earn a guaranteed $1.75 million for the betterment of the Gulf Coast.

---

This article originally appeared on CultureMap.com.

Kids, kicks and connectivity: Xfinity makes soccer a shared experience

The Beautiful Game

For soccer mom Lana Chase, weekends were a whirlwind of cleats, carpooling, and cheering from the sidelines. Now that her daughter Miah graduated high school in May, the Chase Family’s love for the game hasn't stopped. It's shifted to their living room, where Comcast’s new Xfinity streaming platform brings the global game home.

“We’re a soccer family through and through,” says Chase. “Miah played soccer from about age 8 until 16, and we love the World Cup! Xfinity makes it easy for all of us to watch what we love together.”

One platform, every goal

Xfinity's new World Soccer Ticket package eliminates the chaos of juggling apps, subscriptions, or subpar streams. Families can now enjoy more than 1,500 matches from across the globe.

With parental controls, age-appropriate content, and smart recommendations, Xfinity turns soccer into family-friendly entertainment. Whether it’s a weekend watch party or a quiet school night, the platform adapts to every household’s rhythm.

“Figuring out where to watch your favorite team or match is often a painful game of chance. Now, with World Soccer Ticket, there’s no better way to watch the beautiful game than with Xfinity,” says Jon Gieselman, chief growth officer for Comcast's connectivity & platforms. “It’s easy, we did the work for our customers and pulled together the most coveted leagues and tournaments – from Premier League, LALIGA and Champions League to the World Cup – and put them in one place. We added some magic to the experience, with innovations like Multiview, 4K, and Sports Zone all easily accessible with one simple click or voice command.”

World Cup in Houston

With the 2026 World Cup on the horizon, the timing couldn't have been better. The world tournament will be the largest Spanish-language coverage ever offered by Telemundo, powered by Comcast NBCUniversal's technology, storytelling, and scale.

Telemundo and Peacock hold the exclusive Spanish language rights to "el Mundial," including all 104 matches streaming live on Peacock, with 92 matches airing on Telemundo and 12 on Universo. Live crews will cover every event in all 16 host cities, including Houston.

Xfinity customers will have access to pregame, halftime, and postgame coverage with unprecedented immersive experiences. The 2026 World Cup will be the most exciting event of the summer.

"We know other soccer families who watch matches with their little brothers and sisters. It’s not just a game, it’s family time. It's an even bigger deal with the tournament being just down the road in Houston next year,” Chase adds.

Comcast’s AI-powered platform personalizes the viewing experience, recommending matches and highlights based on each family member’s preferences.

World Soccer Ticket is available for an all-in monthly price of $85. It includes nearly 60 broadcast, cable news, and English- and Spanish-language sports channels, and a subscription to Peacock Premium so customers can enjoy a huge collection of movies, shows, news, and other live sports alongside all their favorite soccer programming.

Subscribe to World Soccer Ticket here.

Houston digital health platform Koda closes $7 million funding round

fresh funding

Houston-based digital advance care planning company Koda Health has closed an oversubscribed $7 million series A funding round.

The round, led by Evidenced, with participation from Mudita Venture Partners, Techstars and Texas Medical Center, will allow the company to scale operations and expand engineering, clinical strategy and customer success, according to a news release.

“This funding allows us to create more goals-of-care product lines, expand our national footprint, and bring goal-concordant care to millions more patients and families," Tatiana Fofanova, co-founder and CEO of Koda Health, said in the release.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, has seen major growth this year and said it now supports more than 1 million patients nationwide. The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April and with Epic Systems in July. Users of Epic's popular Mychart system and Guidehealth's clinically integrated networks can now document and share their care preferences, goals and advance directives for health systems using Koda Health's platform. It also has partnerships with Cigna, Privia and Memorial Hermann.

The company shared that the recent series A "marks a pivotal moment," as it has secured investments from influential leaders in the healthcare and venture capital space.

“Koda is the only company combining technology and service to deliver comprehensive solutions that help health plans, providers, and health systems scale goals-aligned care. With satisfied customers expanding their partnerships and policy shifts reinforcing the need for patient-centered care that also contains costs, we couldn’t be more excited to support the Koda team and their vision,” Sean Glass, managing partner at Evidenced, said in the release.

According to the company, a recent peer-reviewed study with Houston Methodist ACO showed that the platform can have a major impact on palliative care results and costs. The findings showed:

79 percent reduction in terminal hospitalizations
20 percent decrease in inpatient length of stay
51 percent increase in hospice use among decedents
Nearly $9,000 in average savings per patient

“Patients long for clarity, families deserve peace of mind, and providers demand ease of use,” Dr. Desh Mohan, chief medical officer of Koda Health, added in the release. “At Koda, we make it possible to deliver all three — transforming Advance Care Planning into a compassionate, ongoing dialogue that honors patients and supports families every step of the way.”

Koda Health also closed an oversubscribed seed round for an undisclosed amount last year, with investments from AARP, Memorial Hermann Health System and the Texas Medical Center Venture Fund. Read more here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME